Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...

From role models to open doors, Christina Y. Weng, MD, MBA, FASRS, shares insights on career development, women in ophthalmology, evolving training models, and her work as protocol chair for the DRCR ...

Expert retina specialists discuss recent developments in the treatment landscape for geographic atrophy (GA) and the future management of patients with coexisting neovascular AMD and GA.

The biosimilar now known by the brand name OPUVIZ was previously known as the biosimilar candidate SB15. The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial.

The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

Adrienne Scott, MD, and Prethy Rao, MD, MPH, discuss implementation of step therapy in neovascular age-related macular degeneration and diabetic macular edema without compromising vision outcomes.

Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao share their approaches to dosing recommendations for faricimab in the treatment of neovascular AMD.

Valerie Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency department can provide timely, accurate diagnosis while also benefiting the ...

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials. Breye Therapeutics announced the successful ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...

Nimesh A. Patel, MD, FASRS, from Mass Eye and Ear Hospital and Boston Children's Hospital presented a real-world study using the Vestrum database to examine usage trends for pegcetacoplan and ...